Geleen, Netherlands

Jurgen Mateman

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fresenius Kabi Ipsum S.r.l.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jurgen Mateman. Retrieved from https://idiyas.com/inventor/jurgen-mateman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jurgen Mateman: Innovator in Biochemistry

Introduction

Jurgen Mateman is a notable inventor based in Geleen, Netherlands. He has made significant contributions to the field of biochemistry, particularly through his innovative work on subtilisin variants.

Latest Patents

Jurgen holds a patent for "Subtilisin Variants and Their Use." This patent showcases his expertise in enzyme technology and its applications in various industries.

Career Highlights

Jurgen Mateman is currently employed at Fresenius Kabi Ipsum S.r.l., where he continues to push the boundaries of biochemistry. His work has been instrumental in developing new solutions that enhance the efficacy of biopharmaceuticals.

Collaborations

Throughout his career, Jurgen has collaborated with talented individuals such as Timo Nuijens and Rowin De Visser. These partnerships have fostered a creative environment that encourages innovation and progress.

Conclusion

Jurgen Mateman's contributions to biochemistry and his innovative patents reflect his dedication to advancing the field. His work at Fresenius Kabi Ipsum S.r.l. and collaborations with esteemed colleagues further highlight his impact on the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…